We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Kallikrein 7 (KLK7) Antibodies|
|Epitope||AA 1-253 Alternatives|
|Conjugate||This Kallikrein 7 antibody is un-conjugated Alternatives|
ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
|Supplier||Log in to see|
Product Details anti-Kallikrein 7 AntibodyTarget Details Kallikrein 7 Application Details Handling Images
|Specificity||Human Kallikrein-7 / KLK7|
|Characteristics||Produced in rabbits immunized with purified, recombinant Human KLK7 (rh KLK7, ABIN2002806 NP_005037.1, Met 1-Arg 253,. KLK7 specific IgG was purified by human KLK7 affinity chromatography .|
|Purification||purified by affinity chromatography|
|Sterility||0.2 μm filtered|
|Immunogen||Recombinant Human KLK7 protein (ABIN2002806)|
Target Details Kallikrein 7Product Details anti-Kallikrein 7 Antibody Application Details Handling Images back to top
|Alternative Name||KLK7 (KLK7 Antibody Abstract)|
|Background||Kallikrein-7, also known as kallikrein-related peptidase 7, Stratum corneum chymotryptic enzyme, Serine protease 6, KLK7, and PRSS6, is a secreted protein which belongs to the,peptidase S1 family and Kallikrein subfamily. Members of the Kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14). Kallikrein-7 / KLK7 appears to be increased in ovarian cancer and higher KLK7 expression in ovarian cancer tissue is associated with poorer prognosis of ovarian cancer patients. Kallikrein-7 / KLK7 is abundantly expressed in the skin and is expressed by keratinocytes in the epidermis. Kallikrein-7 / KLK7 is up-regulated in ovarian carcinoma, especially late-stage serous carcinoma, compared with normal ovaries and benign adenomas (at the protein level). It was significantly associated with shorter overall survival (OS) and disease-free survival (DFS). Kallikrein-7 / KLK7 may catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. KLK7 also plays a role in the activation of precursors to inflammatory cytokines.|
Application DetailsProduct Details anti-Kallikrein 7 Antibody Target Details Kallikrein 7 Handling Images back to top
ELISA: 0.1-0.2 μg/mL
This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human KLK7. The detection limit for Human KLK7 is approximately 0.00245 ng/well.
IHC-P: 0.1-2 μg/mL
|Restrictions||For Research Use only|
HandlingProduct Details anti-Kallikrein 7 Antibody Target Details Kallikrein 7 Application Details Images back to top
|Buffer||0.2 μm filtered solution in PBS with 5 % trehalose|
|Handling Advice||Avoid repeated freeze-thaw cycles.|
|Storage||4 °C,-20 °C,-80 °C|
This antibody can be stored at 2°C-8°C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20°C to -80°C. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
|Expiry Date||12 months|
ImagesProduct Details anti-Kallikrein 7 Antibody Target Details Kallikrein 7 Application Details Handling back to top